Skip to main content

Table 1 Demographic and clinical data at baseline

From: Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies

  MCI MCI+ MCI− Mild AD Mild AD+
Number of subjects (100 %) 382 206 176 97 90
Female (%) 43 % 42 % 45 % 45 % 48 %
Caucasian, n (%) 94 % 97 % 90 % 96 % 96 %
Age, yr 71.97 ± 7.39 72.97 ± 7.10 70.80 ± 7.56 75.17 ± 7.70 74.85 ± 7.66
Education, yr 16.28 ± 2.59 16.31 ± 2.62 16.25 ± 2.55 15.52 ± 2.60 15.51 ± 2.58
ApoE4 at risk,a n (%) 177 (46 %) 142 (69 %) 35 (20 %) 67 (69 %) 65 (72 %)
MMSE 27.85 ± 1.75 27.41 ± 1.82 28.37 ± 1.52 23.19 ± 1.99 23.14 ± 1.99
CDR global 0.50 ± 0.00 0.50 ± 0.00 0.50 ± 0.00 0.77 ± 0.28 0.77 ± 0.28
CDR-SB 1.40 ± 0.84 1.56 ± 0.92 1.21 ± 0.70 4.40 ± 1.71 4.41 ± 1.65
ADAS-Cog 11 9.50 ± 4.29 10.83 ± 4.46 7.94 ± 3.50 19.66 ± 6.30 20.14 ± 6.26
ADAS-Cog 3 8.23 ± 3.76 9.43 ± 3.92 6.82 ± 3.02 15.95 ± 4.15 16.28 ± 4.12
ADAS-Cog 5 13.96 ± 6.17 16.12 ± 6.28 11.43 ± 4.99 26.20 ± 5.31 26.62 ± 5.23
ADAS-Cog 13 15.23 ± 6.68 17.52 ± 6.81 12.55 ± 5.43 29.91 ± 7.44 30.52 ± 7.35
  1. amyloid-β, AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ApoE4, apolipoprotein E ε4, CDR Clinical Dementia Rating, MCI mild cognitive impairment, MMSE Mini Mental State Examination, SB Sum of Boxes
  2. Populations enriched based on t- Tau/Aβ ratio are labelled as MCI+ and AD+. Data are presented as mean ± standard deviation unless indicated otherwise
  3. aApoE4 status is not available for one subject in the MCI group